Tiziana Life Sciences Ltd
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TLSA | ZURA | TVGN | ACTI.ST | IMUX | CHRS | |
|---|---|---|---|---|---|---|
| Market cap | 81.19M | 387.23M | 95.87M | 102.54M | 108.34M | 131.36M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.5 | -5.9 | — | — | -3.4 | -1.3 |
| Price/book | -30.4 | 2.2 | -1.4 | 2.8 | 0.8 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −62.50% | +15.52% | −75.61% | −34.67% | +13.27% | −42.95% |
| Today | −7.55% | +0.75% | −3.38% | +5.71% | +4.47% | +5.54% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TLSA news ›Tiziana Life Sciences reports positive phase 2a results for Intranasal Foralumab in MS
Proactive has a commercial relationship with Tiziana Life Sciences Ltd. This article was produced independently under Proactive's Editorial Standards Policy. Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to…
Tiziana falters following mid-stage results for multiple sclerosis asset
Tiziana Life Sciences stock fell after phase 2a multiple sclerosis trial results. Read more here. - Tiziana Life Sciences (TLSA) is down ~13% in Monday trading despite reporting phase 2a results that met its dual primary endpoints for…
Teva to halt Phase II MSA therapy trial after futility analysis
Teva Pharmaceuticals has announced plans to halt a Phase II clinical trial evaluating emrusolmin (TEV-‘286) to treat adults with multiple system atrophy (MSA), after an interim analysis found the study was unlikely to meet its primary…
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company deve... Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal…
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ... Tiziana Life Sciences Announces…
Tiziana Life Sciences doses last patient in foralumab trial
Tiziana Life Sciences (TLSA) announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evalu... Tiziana Life Sciences doses last patient in foralumab trial Tiziana Life Sciences (TLSA)…
Tiziana Life Sciences Ltd: Relative Strength Chart - Stock Nasdaq
Compare Tiziana Life Sciences Ltd with the company of your choice via a Relative Strength chart. Real-time TLSA price, Nasdaq stock exchange Relative Strength Chart Tiziana Life Sciences Ltd Biotechnology & Medical Research All financial…
Tiziana Life Sciences Says Executive Chairman Gabriele Cerrone Boosts Stake
Tiziana Life Sciences said Wednesday that founder and Executive Chairman Gabriele Cerrone has purchased 42,357 common shares at $0.99 apiece. Cerrone now holds about 44.8 million common shares,... Tiziana Life Sciences Ltd Biotechnology &…
Tiziana Life Sciences Completes Last Patient Last Visit in Phase 2A Inform-Ms Trial of Intranasal Foralumab
Tiziana Life Sciences announced that the last patient has completed their last visit in the Company?s Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary... Tiziana Life Sciences announced that the…
Tiziana Life Sciences (NASDAQ:TLSA) Upgraded at Wall Street Zen
Posted by Tristan Rich on Oct 27th, 2026 Wall Street Zen upgraded shares of Tiziana Life Sciences (NASDAQ:TLSA – Free Report) from a strong sell rating to a sell rating in a research report report published on Saturday morning,Wall Street…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com6
- marketscreener.com3
- proactiveinvestors.com1
- seekingalpha.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.